Please login to the form below

Not currently logged in
Email:
Password:

Novartis launches once-daily COPD drug in US

Arcapta Neohaler could be blockbuster if pharma company makes most of product’s combination potential

Novartis has launched its once-daily Arcapta Neohaler product in the US for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

The indacaterol-based product – formerly known as QAB149 – was approved by the FDA last July and is claimed to be the first once-daily, 24-hour long-acting beta2-agonist (LABA) class to be approved in the US for this indication.

Andre Wyss, president of Novartis' US subsidiary, said: "The launch of Arcapta Neohaler is a significant milestone as we continue to establish a strong respiratory presence in the US market."

While Arcapta Neohaler is expected to have fairly modest sales as a monotherapy, Novartis is developing combination products with the inhaled corticosteroid mometasone and long-acting muscarinic agonist (LAMA) glycopyrronium bromide and analysts have predicted that these could drive franchise sales up to the blockbuster level at peak.

Currently, the top-selling drugs for COPD are GlaxoSmithKline's beta agonist and corticosteroid combination Advair/Seretide/Adoair (salmeterol/fluticasone) and Boehringer Ingelheim/Pfizer's muscarinic antagonist Spiriva (tiotropium) with sales of around $8bn (including asthma sales) and $4bn respectively last year.

Indacaterol was first approved in 2009 in the EU as the Onbrez Breezhaler, and under that brand has achieved a little over $100m in sales last year.

The situation has been somewhat different in the US though, with the FDA blocking its approval in 2009 on safety concerns.

Then in March 2011 the FDA's Pulmonary-Allergy Drug Advisory Committee backed indacaterol 75 mcg, voting 13 to four in favour of that dose.

However, the panel voted 12 to five against recommending approval of a 150mcg dose of the drug saying its efficacy was equivalent to the lower dose.

Novartis said in a statement that the safety and efficacy of Arcapta Neohaler has been demonstrated in six clinical trials that included 5,474 patients ages 40 and older with a clinical diagnosis of COPD, including more than 2,500 who received Arcapta Neohaler for at least 12 weeks at doses of 75mcg or higher.

There are around 14m people in the US living with COPD, according to the company.

20th March 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptiv Solutions

Aptiv Solutions is a global development services company focused on enhancing clinical trial decision-making, efficiency and productivity for pharmaceutical, biotech...

Latest intelligence

Online Physician Communities
Global cancer conference inspires M3’s largest highlights programme
ASCO initiative spans 16 European countries and five specialties...
Online Physician Communities
M3 improves personalisation of pharma engagement with doctors
Launches new messaging service on Doctors.net.uk...
Digital Futures 2014 slide deck
Full slides, including survey data, from PMLiVE's digital pharma marketing online event...